Piper Sandler Maintains Overweight on PROCEPT BioRobotics, Raises Price Target to $75
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Matt O'Brien has maintained an Overweight rating on PROCEPT BioRobotics (NASDAQ:PRCT) and increased the price target from $67 to $75.

May 06, 2024 | 12:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has reaffirmed its Overweight rating on PROCEPT BioRobotics and raised its price target to $75 from $67.
The increase in price target by a reputable analyst like Matt O'Brien from Piper Sandler typically signals a strong bullish outlook on the stock, suggesting a positive short-term impact on PRCT's stock price. Analyst ratings and price target adjustments are significant indicators for investors, often leading to increased investor confidence and potential stock price movement.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100